{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:45:59Z","timestamp":1789832759712,"version":"4.0.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Merkel cell carcinoma (MCC) is an aggressive skin cancer with a poor prognosis, which only improved with the introduction of immunotherapies. An MCC prediction model with high diagnostic accuracy is lacking. The aim was to develop an MCC prognostic score (MCC-PS) based on combinations of previously proposed risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicentric, retrospective study was conducted to develop MCC-PS, which included age, neuron-specific enolase (NSE), C-reactive protein (CRP), creatinine, bilirubin, and international normalized ratio (INR). Creatinine, bilirubin, and INR were used to calculate the model of end-stage liver disease (MELD) score. A total of 98 patients were included in the study, including 36.7% with stage I according to American Joint Committee on Cancer 2018 (<jats:italic>n<\/jats:italic> = 36), 30.6% with stage II (<jats:italic>n<\/jats:italic> = 30), 25.5% with stage III (<jats:italic>n<\/jats:italic> = 25), and 7.1% with stage IV (<jats:italic>n<\/jats:italic> = 7). Survival data of MCC patients were correlated with selected laboratory parameters and risk factors. Primary endpoint was MCC-specific survival (MSS) and the secondary endpoint was progression-free survival. Several statistical methods were used to develop the prognostic score, including correlation analysis, Kaplan\u2013Meier curves, Cox regression, and time-dependent receiver operating characteristic analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The MCC-PS is based on the sum of the following baseline variables: elevated CRP (\u22655.5 mg\/l), elevated NSE (\u226522.8 \u00b5g\/l), MELD score \u2265 11, and age \u2265 75 years. An MELD score \u2265 11 was scored as 4 points, elevated NSE level as 3 points, elevated CRP level as 2 points, and age \u2265 75 years as 1 point. A high-risk group according to the MCC-PS was characterized by a score of 4 or more points. The high-risk group was associated with a worse prognosis than the low-risk group (1-year MSS 62%, 2-year 43.1%, 5-year 17.6% as compared to 1-year MSS 79.5%, 3-year 75%, 5-year 72%). Notably, the developed MCC-PS predicts MCC outcome measures with high accuracy (3-year MSS: area under the curve (AUC) 0.934, sensitivity 87.5% and specificity 82.2%; 5-year MSS: AUC 0.93, sensitivity 89% and specificity 82%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MCC-PS is the first prognostic score predicting MCC outcome with a high accuracy based on five easily available laboratory parameters and patient\u2019s age. An MCC-PS of 4 or more indicates a high-risk patient associated with a poor prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1427740","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:58:51Z","timestamp":1721624331000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Introducing MCC-PS: a novel prognostic score for Merkel cell carcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Nessr","family":"Abu Rached","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke S.","family":"Lonsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aric","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis A.","family":"Zeglis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Gambichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14930","article-title":"S2k Guideline - Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - Update 2022","volume":"21","author":"Becker","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/S0140-6736(23)00769-9","article-title":"Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial","volume":"402","author":"Becker","year":"2023","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2021.200232","article-title":"Merkel cell polyomavirus and associated Merkel cell carcinoma","volume":"13","author":"Yang","year":"2022","journal-title":"Tumour Virus Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.1152586","article-title":"Clonal integration of a polyomavirus in human Merkel cell carcinoma","volume":"319","author":"Feng","year":"2008","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00858-z","article-title":"Merkel cell carcinoma: integrating epidemiology, immunology, and therapeutic updates","author":"Becker","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246176","article-title":"Epidemiology of Merkel cell polyomavirus infection and Merkel cell carcinoma","volume":"14","author":"Silling","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-03929-y","article-title":"Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma","volume":"148","author":"Gambichler","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123195","article-title":"Model for end-stage liver disease correlates with disease relapse and death of patients with Merkel cell carcinoma","volume":"15","author":"Gambichler","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21717","article-title":"Serum neuron-specific enolase independently predicts outcomes of patients with Merkel cell carcinoma","volume":"187","author":"Gambichler","year":"2022","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes","volume":"38","author":"Riley","year":"2019","journal-title":"Stat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12874-017-0332-6","article-title":"Time-dependent ROC curve analysis in medical research: current methods and applications","volume":"17","author":"Kamarudin","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909093045","article-title":"Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis","volume":"24","author":"Albers","year":"1989","journal-title":"Scand J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11864-021-00826-3","article-title":"Neoadjuvant therapy for non-melanoma skin cancer: updated therapeutic approaches for basal, squamous, and Merkel cell carcinoma","volume":"22","author":"Zelin","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002646","article-title":"First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study","volume":"9","author":"D'Angelo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1427740\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:58:54Z","timestamp":1721624334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1427740\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":22,"alternative-id":["10.3389\/fonc.2024.1427740"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1427740","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"article-number":"1427740"}}